International Journal of Molecular Sciences (May 2024)

Measured and Estimated Glomerular Filtration Rate to Evaluate Rapid Progression and Changes over Time in Autosomal Polycystic Kidney Disease: Potential Impact on Therapeutic Decision-Making

  • Rosa Miquel-Rodríguez,
  • Beatriz González-Toledo,
  • María-Vanessa Pérez-Gómez,
  • María Ángeles Cobo-Caso,
  • Patricia Delgado-Mallén,
  • Sara Estupiñán,
  • Coriolano Cruz-Perera,
  • Laura Díaz-Martín,
  • Federico González-Rinne,
  • Alejandra González-Delgado,
  • Armando Torres,
  • Flavio Gaspari,
  • Domingo Hernández-Marrero,
  • Alberto Ortiz,
  • Esteban Porrini,
  • Sergio Luis-Lima

DOI
https://doi.org/10.3390/ijms25095036
Journal volume & issue
Vol. 25, no. 9
p. 5036

Abstract

Read online

Autosomal polycystic kidney disease (ADPKD) is the most common genetic form of kidney failure, reflecting unmet needs in management. Prescription of the only approved treatment (tolvaptan) is limited to persons with rapidly progressing ADPKD. Rapid progression may be diagnosed by assessing glomerular filtration rate (GFR) decline, usually estimated (eGFR) from equations based on serum creatinine (eGFRcr) or cystatin-C (eGFRcys). We have assessed the concordance between eGFR decline and identification of rapid progression (rapid eGFR loss), and measured GFR (mGFR) declines (rapid mGFR loss) using iohexol clearance in 140 adults with ADPKD with ≥3 mGFR and eGFRcr assessments, of which 97 also had eGFRcys assessments. The agreement between mGFR and eGFR decline was poor: mean concordance correlation coefficients (CCCs) between the method declines were low (0.661, range 0.628 to 0.713), and Bland and Altman limits of agreement between eGFR and mGFR declines were wide. CCC was lower for eGFRcys. From a practical point of view, creatinine-based formulas failed to detect rapid mGFR loss (−3 mL/min/y or faster) in around 37% of the cases. Moreover, formulas falsely indicated around 40% of the cases with moderate or stable decline as rapid progressors. The reliability of formulas in detecting real mGFR decline was lower in the non-rapid-progressors group with respect to that in rapid-progressor patients. The performance of eGFRcys and eGFRcr-cys equations was even worse. In conclusion, eGFR decline may misrepresent mGFR decline in ADPKD in a significant percentage of patients, potentially misclassifying them as progressors or non-progressors and impacting decisions of initiation of tolvaptan therapy.

Keywords